



James Lott, PharmD
Fiduscript, A Public Benefit Corporation
4220 S King Dr. #1S
Chicago, IL 60653

National Academy of Medicine
733 10th Street NW, Suite 700
Washington DC, 20001

ATTENTION:
Action Collaborative on Countering the U.S. Opioid Epidemic

April 30, 2019

Dear National Academy of Medicine,

My name is James Lott, the Founder & CEO of Fiduscript, a Public Benefit Corporation that aims to expand access to life-saving resources for substance users, and their loved one's online. Since January 2018, our team has been working diligently to develop an idea into a consumer service that saves lives: Naloxone Exchange by Fiduscript. Naloxone Exchange (<http://www.naloxoneexchange.com>) is an online marketplace where anyone can legally purchase the life-saving medication naloxone, receive effective training, and have it delivered to their door. As of October 24, 2018, Naloxone Exchange has been approved by five state boards of pharmacy throughout the country, and each month we aim to increase that number. We are also considered a ".pharmacy" verified safe service designated by the National Associations of Boards of Pharmacy.

Myself being a pharmacist, and our team thought the public could benefit from Naloxone Exchange, as we hypothesized that stigma, and coverage gaps were significant barriers to accessing naloxone, and then later confirmed it by creating a survey, which we then distributed to over 500 substance users, and their loved one's online. We received responses from 48/50 states and from our survey results (which we have not yet published), we learned that the majority of naloxone candidates do not want to interact directly with a doctor or pharmacist about their substance use, however they do want to receive adequate training on how to use the medication. We also learned that the majority would be willing to purchase the medication.

Using our survey results we designed Naloxone Exchange to meet our patient and consumers needs. We also understand that responsible public and private enterprises want to procure the life-saving drug but often have trouble getting naloxone due to cost, or legal issues because of Naloxone prescription status. Through Naloxone Exchange, we are happy to report that we have systems in place to bridge the gap and overcome these barriers. We work directly with manufacturers to procure the lowest price for the drug, and have a pharmacy partner who is readily available to answer questions, and has all required licensure (pending state board of pharmacy approval of Naloxone Exchange within the specific state) to distribute Naloxone to all fifty states once boards approve our service. With our HIPAA secure platform, we make it easy for any individual, or entity to get access and training to the life-saving medication via standing order prescriptions.

We ask that we can find ways to partner with the National Academy of Medicine, as we have also done with the Clinton Foundation, Google, Stanford Medicine, and the University of Chicago. We hope that this note finds you well, and we look forward to launching our service in Q2 2019, expanding access and saving lives. Please contact us for any follow-up questions or concerns you may have.

Best,

James Lott PharmD
Founder & CEO, Fiduscript PBC